Driven by HESI, FDA and Safety Pharmacology Society, the CiPA initiative aims to evaluate potential modifications to current regulatory FDA guidelines for cardiac safety assessment. The xCELLigence RTCA CardioECR was selected as a core technology for validation and has participated in Phase I and II.
Real-Time Cell Analysis for Cardiovascular Research
Real-time, functional cell analysis of cardiomyocytes provides novel and sensitive measurements for cardiac disease research to reveal critical pathways and identify drug targets.
With Agilent cell analysis technologies, expand your drug development pipeline by examining drug compounds affecting contractile processes, cardiotoxicity, cardiovascular disease, and cardiac safety. Perform disease-specific modeling with human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) to understand the underlying causes of these cardiomyopathies.